Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
GlaxoSmithKline ( (GSK) ) has issued an update.
On January 20, 2025, GSK announced that the European Commission has expanded its approval of Jemperli (dostarlimab) in combination with chemotherapy for the treatment of primary advanced or recurrent endometrial cancer. This expansion includes the majority of patients with mismatch repair proficient/microsatellite stable (MMRp/MSS) tumors, which constitute about 75% of such cases. The decision is based on the RUBY Part 1 trial, which demonstrated a significant overall survival benefit with Jemperli plus chemotherapy compared to chemotherapy alone. This marks a significant advancement in treatment options, providing an immuno-oncology-based option for patients who previously had limited alternatives. The approval is expected to impact GSK’s positioning in the oncology market, potentially enhancing its leadership in gynecologic cancer treatment.
More about GlaxoSmithKline
GlaxoSmithKline (GSK) is a leading global healthcare company engaged in the research, development, and manufacturing of pharmaceuticals, vaccines, and consumer healthcare products. The company is heavily focused on immuno-oncology, a field that uses the body’s immune system to fight cancer, with its product Jemperli being a core part of its research and development efforts.
YTD Price Performance: -1.53%
Average Trading Volume: 5,430,261
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $67.83B
For an in-depth examination of GSK stock, go to TipRanks’ Stock Analysis page.
